eScholarship@UMMS

Title

A proteasome inhibitor, bortezomib, inhibits breast cancer growth and reduces osteolysis by downregulating metastatic genes

Authors

Marci D. Jones, University of Massachusetts Medical SchoolFollow
Julie C. Liu, University of Massachusetts Medical School
Thomas K. Barthel, University of Massachusetts Medical SchoolFollow
Sadiq Hussain, University of Massachusetts Medical SchoolFollow
Erik Lovria, University of Massachusetts Medical SchoolFollow
Dengfeng Cheng, University of Massachusetts Medical SchoolFollow
Jesse A. Schoonmaker, Massachusetts General Hospital,
Sudhanshu Mulay, Massachusetts General Hospital,
David C. Ayers, University of Massachusetts Medical SchoolFollow
Mary L. Bouxsein, Harvard University
Gary S. Stein, University of Massachusetts Medical SchoolFollow
Siddhartha Mukherjee, Columbia University
Jane B. Lian, University of Massachusetts Medical SchoolFollow

UMMS Affiliation

Department of Cell Biology; Department of Orthopedics and Physical Rehabilitation

Publication Date

2010-09-17

Document Type

Article

Subjects

Protease Inhibitors; Boronic Acids; Pyrazines; Breast Neoplasms; Osteolysis

Disciplines

Cell Biology

Abstract

PURPOSE: The incidence of bone metastasis in advanced breast cancer (BrCa) exceeds 70%. Bortezomib, a proteasome inhibitor used for the treatment of multiple myeloma, also promotes bone formation. We tested the hypothesis that proteasome inhibitors can ameliorate BrCa osteolytic disease.

EXPERIMENTAL DESIGN: To address the potentially beneficial effect of bortezomib in reducing tumor growth in the skeleton and counteracting bone osteolysis, human MDA-MB-231 BrCa cells were injected into the tibia of mice to model bone tumor growth for in vivo assessment of treatment regimens before and after tumor growth.

RESULTS: Controls exhibited tumor growth, destroying trabecular and cortical bone and invading muscle. Bortezomib treatment initiated following inoculation of tumor cells strikingly reduced tumor growth, restricted tumor cells mainly to the marrow cavity, and almost completely inhibited osteolysis in the bone microenvironment over a 3- to 4-week period as shown by [(18)F]fluorodeoxyglucose positron emission tomography, micro-computed tomography scanning, radiography, and histology. Thus, proteasome inhibition is effective in killing tumor cells within the bone. Pretreatment with bortezomib for 3 weeks before inoculation of tumor cells was also effective in reducing osteolysis. Our in vitro and in vivo studies indicate that mechanisms by which bortezomib inhibits tumor growth and reduces osteolysis result from inhibited cell proliferation, necrosis, and decreased expression of factors that promote BrCa tumor progression in bone.

CONCLUSION: These findings provide a basis for a novel strategy to treat patients with BrCa osteolytic lesions, and represent an approach for protecting the entire skeleton from metastatic bone disease.

DOI of Published Version

10.1158/1078-0432.CCR-09-3293

Source

Clin Cancer Res. 2010 Oct 15;16(20):4978-89. Epub 2010 Sep 15. Link to article on publisher's site

Journal/Book/Conference Title

Clinical cancer research : an official journal of the American Association for Cancer Research

Related Resources

Link to Article in PubMed

PubMed ID

20843837

Repository Citation

Jones MD, Liu JC, Barthel TK, Hussain S, Lovria E, Cheng D, Schoonmaker JA, Mulay S, Ayers DC, Bouxsein ML, Stein GS, Mukherjee S, Lian JB. (2010). A proteasome inhibitor, bortezomib, inhibits breast cancer growth and reduces osteolysis by downregulating metastatic genes. Stein, Stein, Lian, vanWijnen Lab Publications. https://doi.org/10.1158/1078-0432.CCR-09-3293. Retrieved from https://escholarship.umassmed.edu/stein/6